Collegium Pharmaceutical, Inc. Overview
Pro stress-test →Collegium Pharmaceutical is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company specializes in the development and commercialization of medicines for pain management. The September 2024 acquisition of Ironshore added Jornay PM and expanded Collegium into neuropsychiatry.
Strategic Profile
Pro stress-test →Collegium is engaged in developing and commercializing abuse-deterrent products incorporating its patented DETERx platform technology, designed to maintain extended-release and safety profiles in the face of various abuse methods. Disciplined acquisitions and targeted investments in ADHD therapies diversify the portfolio and reduce risk, supporting stable long-term earnings.
Competitive Landscape
Pro stress-test →SCILEX Holding, Lannett Company, Pfizer Manufacturing Austria, and Acura Pharmaceuticals are among Collegium's 32 competitors. As a specialty pharmaceutical company focused on pain management, Collegium competes in the prescription pain management and abuse-deterrent opioid segments. Over the past year, COLL exceeded both the US Pharmaceuticals industry return of 25.1% and the US Market return of 15.5%.
Industry Context
Collegium Pharmaceutical, Inc. operates in Specialty Pharmaceuticals - Pain Management & Neuropsychiatry.
Key facts
Founded: 2002 · Headquarters: Stoughton, MA · Revenue: $757M · Market cap: $1.46B